Last reviewed · How we verify
rifapentine and moxifloxacin
rifapentine and moxifloxacin is a fluoroquinolone Small molecule drug developed by Centers for Disease Control and Prevention. It is currently in Phase 3 development for Treatment of latent tuberculosis infection, Treatment of active tuberculosis disease. Also known as: Priftin and Avelox.
Rifapentine is a bactericidal antibiotic that inhibits DNA-dependent RNA polymerase, while moxifloxacin is a bactericidal antibiotic that inhibits DNA gyrase and topoisomerase IV.
Rifapentine is a bactericidal antibiotic that inhibits DNA-dependent RNA polymerase, while moxifloxacin is a bactericidal antibiotic that inhibits DNA gyrase and topoisomerase IV. Used for Treatment of latent tuberculosis infection, Treatment of active tuberculosis disease.
At a glance
| Generic name | rifapentine and moxifloxacin |
|---|---|
| Also known as | Priftin and Avelox |
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | fluoroquinolone |
| Target | DNA-dependent RNA polymerase, DNA gyrase, topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Rifapentine and moxifloxacin work by targeting bacterial DNA replication and transcription. Rifapentine specifically inhibits the RNA polymerase enzyme, which is essential for bacterial RNA synthesis. Moxifloxacin, on the other hand, inhibits DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication and transcription.
Approved indications
- Treatment of latent tuberculosis infection
- Treatment of active tuberculosis disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Headache
Key clinical trials
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
- Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis (PHASE2)
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens (PHASE3)
- Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB (PHASE3)
- Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T) (PHASE2, PHASE3)
- Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rifapentine and moxifloxacin CI brief — competitive landscape report
- rifapentine and moxifloxacin updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about rifapentine and moxifloxacin
What is rifapentine and moxifloxacin?
How does rifapentine and moxifloxacin work?
What is rifapentine and moxifloxacin used for?
Who makes rifapentine and moxifloxacin?
Is rifapentine and moxifloxacin also known as anything else?
What drug class is rifapentine and moxifloxacin in?
What development phase is rifapentine and moxifloxacin in?
What are the side effects of rifapentine and moxifloxacin?
What does rifapentine and moxifloxacin target?
Related
- Drug class: All fluoroquinolone drugs
- Target: All drugs targeting DNA-dependent RNA polymerase, DNA gyrase, topoisomerase IV
- Manufacturer: Centers for Disease Control and Prevention — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of latent tuberculosis infection
- Indication: Drugs for Treatment of active tuberculosis disease
- Also known as: Priftin and Avelox